This book explores the crucial role that Human Epidermal Growth Factor Receptor 2 (HER2) plays in the initiation and progression of cancer, as well as cutting-edge molecular mechanisms, precision medicine, and novel targeted treatments, including lapatinib, pertuzumab, and trastuzumab. HER2 overexpression, especially for breast cancer and beyond, in combination with other development therapies, antibody-drug conjugates, and overcomes resistance mechanisms. This book provides comprehensive coverage of the PI3K/AKT and MAPK signaling pathways, up-to-date information on next-generation HER2 inhibitors, including neratinib and tucatinib, and offers helpful advice for researchers and clinicians managing HER2-positive tumors. This book, which links laboratory findings with clinical applications and offers hope for better outcomes in HER2-driven cancers, is an essential resource for oncologists, molecular biologists, and pharmaceutical scientists. It does so clearly and understandably.

This book is included in DOAB.